Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $1.7 billion.

  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity rose 783.37% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 590.1%. This contributed to the annual value of $1.6 billion for FY2024, which is 426.71% up from last year.
  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.7 billion in Q3 2025, which was up 783.37% from $1.6 billion recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.7 billion during Q3 2025, and registered a low of $645.7 million during Q1 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $1.1 billion, with a median of $1.4 billion in 2023.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 11255.59% in 2023 and then grew by 3.53% in 2024.
  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $671.5 million in 2021, then grew by 10.49% to $742.0 million in 2022, then soared by 103.9% to $1.5 billion in 2023, then rose by 4.27% to $1.6 billion in 2024, then rose by 5.63% to $1.7 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.7 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and $1.6 billion in Q1 2025.